6Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002, 100: 1014-1018.
7von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia- chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002,359: 487-491.
8Roumiantsev S, Shah NP, Gorre ME, et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Pr~ Nat Acad Sci U S A, 9002, 99: 1 0700-10705.
9Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI571 eancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001, 293: 876-880.
10Branford S, Rudzki Z, Walsh S, et al. High frequency of point mutations clustered within the adenosine triphosphate binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Bloot, 2002, 99: 3472-3475.
